Surrogate endpoints: Wishful thinking or reality?

Statistical Methods in Medical Research

Volumn 17, Issue 5, 2008, Pages 463-466

  Burzykowski, Tomasz ^a  

^a HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; INTERFERON; LEVAMISOLE; RALTITREXED; SEMUSTINE; VINCRISTINE;

ADVANCED CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; HUMAN; MONOTHERAPY; NULL HYPOTHESIS; OUTCOMES RESEARCH; OVERALL SURVIVAL; RISK BENEFIT ANALYSIS; SURVIVAL RATE; VALIDATION STUDY;

EID: 52649101507     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280207081866     Document Type: Editorial

References (14)

1. Baker S.G., Kramer B.S. A perfect correlate does not make a surrogate. BioMed Central Medical Reseach Methodology 2003; 3: 16.
2. Burzykowski T., Molenberghs G., Buyse M. The Evalutation of Surrogate Endpoints. Springer, 2005.
3. Prentice R.L. Surrogate endpoints in clinical trials: definitions and operational criteria. Statistics in Medicine 1989; 8: 431-40.
4. Freedman L.S., Graubard B.I., Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 1992; 11: 167-78.
5. Buyse M., Molenberghs G. The validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54: 1014-29.
6. Molenberghs G., Buyse M., Geys H., Renard D., Burzykowski T., Alonso A. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Controlled Clinical Trials 2002; 23: 607-25.
7. Daniels M.J., Hughes M.D. Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 1997; 16: 1515-1527.
8. Buyse M., Molenberghs G., Burzykowski T., Renard D., Geys H. The validation of surrogate endpoints in meta-analysis of randomized experiments. Biostatistics 2000; 1: 49-67.
9. Gail M.H., Pfeiffer R., van Houwelingen H.C., Carroll R.J. On meta-analytic assessment of surrogate outcomes. Biostatistics 2000; 1: 231-46.
10. Baker S.G. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint. Biostatstics 2000; 7: 58-70.
11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapy 2001; 69: 89-95.
12. Sargent D.J., Wieand H.J., Haller D.G., Gray R. Disease-free survival versus overall survival as a primary endpoint for adjuvant colon cancer studies: individual patient data form 20,898 patients on 18 randomized trials. Journal of Clinical Oncology 2005; 23: 8664-70.
13. Meta-Analysis Group In Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Journal of Clinical Oncology 2004; 22: 3766-75.
14. Cunningham D., Zalcberg J., Maroun J., James R., Clarke S., Maughan T.S., Vincent M., Schulz J., Gonzalez B.M., Facchini T. Efficacy, tolerability and management of raltitrexed (TomudexTM) monotherapy in patients with advanced colorectal cancer: a review of phase II / III trials. European Journal of Cancer 2002; 38: 478-86.